Pub. Date : 2020 Apr
PMID : 32085993
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 2 | BACKGROUND: Midostaurin, a multikinase inhibitor, is approved for treatment of FLT3-mutant acute myeloid leukemia (AML). | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 3 | CONCLUSION: Multiple cycles of azacitidine and midostaurin were not well-tolerated, but persistent inhibition of FLT3 wild-type phosphorylation suggest intermittent dosing of midostaurin should be considered in future low-intensity regimens for FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |
| 4 | CONCLUSION: Multiple cycles of azacitidine and midostaurin were not well-tolerated, but persistent inhibition of FLT3 wild-type phosphorylation suggest intermittent dosing of midostaurin should be considered in future low-intensity regimens for FLT3-mutant AML. | midostaurin | fms related receptor tyrosine kinase 3 | Homo sapiens |